Research News

Research News | Aug. 16, 2013

Adult Stems Cells in the Treatment of Lupus - Where are we now?

Cell based therapies are a growing interest in all areas of medicine as they are viewed as long term solutions rather than temporary fixes. A recent journal article highlights progress made in better understanding the potential for two basic types of adult stem cells.

Research News | Aug. 15, 2013

Pilot Study Sheds Light on a Potential New Approach for Treating Lupus Nephritis

Lupus nephritis, which can damage and scar the kidneys, is one of the most common and serious complications of lupus. This new study suggests that with the right induction regimen, it may be possible to avoid maintenance (long-term) treatment with oral steroids.

Research News | Jan. 10, 2013

Study explores lupus treatments and disease activity as risk factors for lymphoma

A new study sheds light on the specific effects of drug treatments versus disease activity as risk factors for lymphoma, a type of cancer, among people with lupus.

Research News | Nov. 08, 2012

Steroid-Related Risk of Heart Disease in Lupus

The results of this study indicate that current use of steroids (20 mg/day or more) is perhaps the most significant risk factor for heart disease in individuals with lupus.

Research News | Sep. 18, 2012

Rontalizumab: A Potential New Lupus Therapy

Rontalizumab is a potential new drug to treat lupus. It reduces the effects of the excessive interferon-alpha that is so characteristic of lupus. The researchers hoped to learn about the safety and tolerability of rontalizumab in people with mild lupus disease activity.

Research News | Aug. 15, 2012

Lupus-Related Changes in Energy Metabolism

People with lupus may experience chronic fatigue, the exact causes of which are yet to be fully understood. There are a number of different energy-producing metabolic processes that may be affected in people with lupus.

Research News | Aug. 15, 2012

Short-Term Use of Hydroxychloroquine Reduces Cholesterol in Lupus

People with lupus are at increased risk of cardiovascular disease, especially when taking steroids. The use of anti-malarial drugs, such as hydroxychloroquine, significantly reduces this risk.

Research News | Jul. 17, 2012

Long-Term Safety of Benlysta®

This study examined the long-term safety of belimumab over a 4-year period in people with lupus. The results highlight the long-term safety of belimumab over a 4-year period.